Thoracoscopic Segmentectomy Within an Enhanced Recovery Pathway Improves Days Alive and Out of Hospital Compared with Lobectomy
Open Access
- 5 February 2026
- journal article
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (2)
Abstract
Objectives: This study aims to investigate the first 90 days alive and out of hospital (DAOH90) following enhanced recovery thoracoscopic segmentectomy versus lobectomy. Methods: A retrospective analysis for consecutive thoracoscopic segmentectomies and lobectomies for clinical stage IA1-2 non-small cell lung cancer (cIA1-2 NSCLC) was performed between January 2018 and March 2024. All factors contributing to reduced DAOH90 were analyzed individually. The association between surgical extent and DAOH90 was assessed using a multivariable logistic regression model. Sensitivity analyses were performed after propensity score matching. Results: Of 720 patients, 591 underwent lobectomy and 129 underwent segmentectomy. Compared with lobectomy, patients undergoing segmentectomy had poorer lung function and exercise capacity, more comorbidities, slightly longer operative duration, and less blood loss. The median DAOH90 was 1 day longer after segmentectomy than lobectomy (87 vs 86 days, P = .049). Air leak > 1 day (38.3% vs 40.0%), pneumonia (13.3% vs 18.3%), and pain (13.3% vs 23.3%) were important reasons to reduce DAOH90, all occurring more frequently in the lobectomy group. Social factors (37.5% vs 25.8%) were also a predominant cause in both groups, particularly after segmentectomy. Other causes were less common. In multivariable analysis, lobectomy (vs segmentectomy, OR 1.44, P = .048) was identified as an independent predictor of shorter DAOH90, along with body mass index, lung function, and cardiac comorbidity. The results of the sensitivity analysis were consistent with these findings. Conclusions: Following an enhanced recovery thoracoscopic protocol, segmentectomy for well-selected patients with cIA1-2 NSCLC may result in longer DAOH and less postoperative complications compared to lobectomy.Keywords
This publication has 17 references indexed in Scilit:
- Why do patients stay in hospital after enhanced recovery thoracoscopic wedge resection? A prospective observational studyEuropean Journal of Cardio-Thoracic Surgery, 2024
- Days alive and out of hospital after video-assisted thoracoscopic surgery wedge resection in the era of enhanced recoveryBJS Open, 2023
- Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung CancerNew England Journal of Medicine, 2023
- Real-world perioperative outcomes of segmentectomy versus lobectomy for early-stage lung cancer: a propensity score-matched analysisEuropean Journal of Cardio-Thoracic Surgery, 2022
- Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trialThe Lancet, 2022
- Days alive and out of hospital after enhanced recovery video-assisted thoracoscopic surgery lobectomyEuropean Journal of Cardio-Thoracic Surgery, 2022
- Thoracoscopic segmentectomy versus lobectomy: A propensity score–matched analysisJTCVS Open, 2022
- Comparison of operative and postoperative characteristics and outcomes between thoracoscopic segmentectomy and lobectomy for non-small-cell lung cancer: a propensity score matching study from the Italian VATS Group RegistryEuropean Journal of Cardio-Thoracic Surgery, 2021
- Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trialThe Journal of Thoracic and Cardiovascular Surgery, 2019
- Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)The Lancet Respiratory Medicine, 2018